Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

See allHide authors and affiliations

Science  11 Nov 1994:
Vol. 266, Issue 5187, pp. 1024-1027
DOI: 10.1126/science.7973652


The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.

Stay Connected to Science